FDA Approves Agilent Complementary Dx for Two Additional Indications

Sep 19, 2017

|

NEW YORK (GenomeWeb) – Agilent Technologies announced today that the US Food and Drug Administration has approved its Dako PD-L1 IHC 28-8 pharmDx complementary diagnostic for two additional indications: urothelial carcinoma (UC) and squamous cell carcinoma of the head and neck (SCCHN).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

FDA Approves Agilent Complementary Dx for Two Additional Indications

To read the full story....

Breaking News

Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Featured White Papers

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

Roche SARS-CoV-2 Lateral Flow Antigen Test Could Meet Significant Demand

BARDA Awards $684K to Luminex for Enhanced COVID-19 Multiplex Antibody Test

BGI Genomics Gets CE Mark for Multiplexed SARS-CoV-2, Influenza Tests

FDA Grants Emergency Use Authorizations for Quadrant Biosciences, KimForest Coronavirus Tests

FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

Sponsorships